Wealth Alliance LLC Reduces Holdings in AbbVie Inc. $ABBV

Wealth Alliance LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,579 shares of the company’s stock after selling 2,659 shares during the quarter. AbbVie makes up 0.6% of Wealth Alliance LLC’s investment portfolio, making the stock its 29th largest position. Wealth Alliance LLC’s holdings in AbbVie were worth $5,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Vanguard Group Inc. increased its stake in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the period. Geode Capital Management LLC grew its holdings in AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after acquiring an additional 1,517,222 shares during the period. Norges Bank bought a new position in shares of AbbVie during the second quarter valued at about $4,288,200,000. Finally, Raymond James Financial Inc. boosted its holdings in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $224.62 on Friday. The stock has a market cap of $396.99 billion, a P/E ratio of 95.29, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50-day moving average of $224.01 and a 200 day moving average of $221.70.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio is 293.22%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ABBV. BMO Capital Markets restated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Scotiabank initiated coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, UBS Group reduced their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $252.79.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approves the all‑oral combination of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated CLL — a first‑in‑class, fixed‑duration regimen supported by Phase 3 AMPLIFY data. This expands AbbVie’s addressable hematology market, could drive incremental high‑margin sales and offers a differentiated product profile (time off therapy). U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Coverage noting the FDA approval frames the combo as potentially setting a new standard for slow‑growing blood cancers, highlighting improved three‑year outcomes versus chemo and the commercial upside if physicians adopt an oral, fixed‑duration approach. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: Board declared a quarterly cash dividend of $1.73/share (ex‑div April 15) — reinforces AbbVie’s income profile (Dividend King status) and supports the stock’s appeal to yield‑focused investors. AbbVie Declares Quarterly Dividend
• Positive Sentiment: VOLITE skin‑quality trial completion update suggests progress in AbbVie’s dermatology pipeline (potential incremental indications/label expansion), a longer‑term earnings catalyst if follow‑up data are positive. AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
• Neutral Sentiment: Company launched a healthcare‑innovation podcast (“The Persistence Lab”) — useful for brand/ stakeholder engagement but unlikely to move near‑term fundamentals. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Neutral Sentiment: Investor pieces encouraging a reassessment of AbbVie’s post‑Humira pipeline highlight progress but are mixed on timing and magnitude of offset to Humira’s legacy revenues — suggests potential upside if execution continues but not guaranteed. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Negative Sentiment: Evercore trimmed its price target slightly (from $232 to $228) and flagged that Tremfya’s market‑share gains may not translate into strong long‑term earnings growth — this analyst caution can weigh on sentiment given AbbVie’s recent valuation and investor focus on growth after Humira. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.